Navigation Links
PharmaPoint: Dry Eye Syndrome - UK Drug Forecast and Market Analysis to 2022
Date:12/4/2013

London (PRWEB) December 04, 2013

PharmaPoint: Dry Eye Syndrome - UK Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, “PharmaPoint: Dry Eye Syndrome - UK Drug Forecast and Market Analysis to 2022”. Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation. The most common symptoms of DES are ocular irritation and discomfort, foreign body sensation, fatigue, and visual disturbances, which interfere with daily activities. In the elderly population, it is the most common reason for seeking eye care, and this is expected to increase exponentially with an aging demographic.

The DES market in the UK is projected to grow substantially during the forecast period. During the forecast period, the primary growth driver of the DES market in the UK will be the launch of the EU’s first prescription product for DES, as well as the rapidly increasing population of DES patients.

Scope

-Overview of the DES including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
-Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.
-Sales forecast for the top drugs in the UK from 2012-2022.
-Analysis of the impact of key events as well the drivers and restraints affecting the UK DES market.

Reasons to buy

-Understand and capitalize by identifying products that are most likely to ensure a robust return
-Stay ahead of the competition by understanding the changing competitive landscape for DES
-Effectively plan your M&A and part
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022
2. PharmaPoint: Alzheimer’s Disease - France Drug Forecast and Market Analysis to 2022
3. PharmaPoint: Dry Eye Syndrome - Current and Future Players
4. PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022
5. PharmaPoint: Non-Small Cell Lung Cancer - UK Drug Forecast and Market Analysis to 2022
6. PharmaPoint: Alzheimer’s Disease - India Drug Forecast and Market Analysis to 2022
7. PharmaPoint: Alzheimer’s Disease - China Drug Forecast and Market Analysis to 2022
8. PharmaPoint: Alzheimer’s Disease - UK Drug Forecast and Market Analysis to 2022
9. PharmaPoint: Chronic Heart Failure - US Drug Forecast and Market Analysis to 2022
10. PharmaPoint: Alzheimer’s Disease - US Drug Forecast and Market Analysis to 2022
11. PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... a researcher from the Cancer Science Institute of Singapore ... identified the cancer specific stem cell which causes gastric ... new drugs for the treatment of this disease and ... by Dr Chan Shing Leng, Research Assistant Professor at ... cancer-specific variant of a cell surface protein, CD44v8-10, marks ...
(Date:4/23/2014)... Oncotarget , explored tumour heterogeneity where different ... signatures within the same cancer. Such differences could ... strategies. , Firstly they confirmed the mutual exclusivity ... or BRAF mutation. Secondly, they found that lung ... that specific mutation present uniformly throughout the tumour, ...
(Date:4/23/2014)... to the bottom of Alzheimer,s disease has been ... and controversies. In the latest crook in the ... into the interaction between proteins associated with the ... ACS Chemical Neuroscience , could have important ... Surewicz, Krzysztof Nieznanski and colleagues explain that for ...
(Date:4/22/2014)... recently FDA-approved device has been shown to reduce seizures ... 50 percent. When coupled with an innovative electrode placement ... facilitated the complete elimination of seizures in nearly half ... clinical trials. , That,s good news for a large ... living with epilepsy whose seizures can,t be controlled with ...
(Date:4/22/2014)... UT Southwestern Medical Center are making breakthroughs that could ... A team of physician-scientists at UT Southwestern has identified ... natural anti-depressant properties) works inside the brain. Simultaneously, the ... in the form of a neuroprotective drug known as ... April,s issue of Molecular Psychiatry, is notable ...
Breaking Medicine News(10 mins):Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3
... in no real danger, survey finds , MONDAY, Aug. 20 ... white peers to take risks that boost their odds for ... August issue of the journal Archives of Dermatology , ... Medicine surveyed 369 high school students (221 white Hispanics and ...
... are exposed to more pro-tobacco advertising, according to a ... this months Public Health Reports. , Smoking remains ... the United States, causing more than 440,000 deaths annually ... indirect costs each year; African-Americans currently bear the greatest ...
... In a study likely applicable to men of other ... than 21 drinks per week) may increase the risk ... study are published in the latest issue of Annals ... Lydia Bazzano of Tulane University School of Public Health ...
... sounds like the latest cleaning sensation being hawked on ... get in your eyes. , But a few properly ... to diagnosing dry eye syndrome earlier than other methods, ... disease, new research at UT Southwestern Medical Center confirms. ...
... to new treatments, study says , SUNDAY, Aug. 19 ... most red, purple and blue fruits and vegetables, may help ... , In laboratory tests on rats and on human colon ... the growth of colon cancer cells. The team also found ...
... It affected 4 indicators of cardiovascular trouble, study found ... air drags down a number of "biological indicators" pointing ... shows. , The indicators include autonomic dysfunction, inflammation, oxidative ... was published Aug. 15 in the American Journal ...
Cached Medicine News:Health News:Hispanic Teens Take More Skin Cancer Risks 2Health News:Pitt study finds inequality in tobacco advertising 2Health News:Eye-staining technique offers early detection for dry eye syndrome 2Health News:Eye-staining technique offers early detection for dry eye syndrome 3Health News:Urban Smog Tough on Young Adults' Hearts 2
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... 31 Millennium Pharmaceuticals, The Takeda,Oncology Company, today ... of VELCADE based therapies that showed consistently high,complete ... multiple,myeloma (MM). CR is one of the best ... for oral presentation at the American Society,of Clinical ...
... reduced the risk of cancer returning or death by 36% beyond clinical ... alone(1) - Findings may allow clinicians to improve standard of care ... ... - These are the first data from a large clinical program exploring ...
Cached Medicine Technology:Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 2Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 3Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 4Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 5Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 6Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 7Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 2Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 3Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 4Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 5Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 6Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 7Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 8Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 9
... German Craftsmanship have produced the ... world. Ocutek now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
... of German Craftsmanship have produced ... the world. Ocutek now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: